Table 6.
Main findings and characteristics of transcriptomic studies of AEs conducted in 2022 (up to 1st October, 2022).
| Biological sample | RNA profiling | Subjects | Phenotype | Main findings | PMID [reference] |
|---|---|---|---|---|---|
|
| |||||
| Nasal blow | RNA-seq (NextSeq 500 platform) |
208 children with asthma from United States | OCS/Hospitalization | Increased SMAD3 expression among children with altered abundance of the two bacterial network was associated with increased exacerbation risk. | 35149044 [114] |
|
| |||||
| Bronchial biopsies | GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix). | 317 participants with severe asthma from Europe | ≥2 events of systemic corticosteroids use vs (frequent exacerbators, FE) <2 events (infrequent exacerbators, IE) |
CEACAM5 expression was increased in FE compared with IE. Higher expression scores for viral infection gene signatures, type 1, T-helper type-17, and type 2 activation pathways in FE compared to IE. Higher expression scores of type 2, type 1 and steroid insensitivity pathway signatures in persistent FE compared to persistent IE. |
35474304 [116] |
Abbreviations: FE: Frequent exacerbators; IE: Infrequent exacerbators; OCS: Oral corticosteroids use; RNA-seq: RNA sequencing.